674 related articles for article (PubMed ID: 11786661)
21. Primary sclerosing cholangitis response to the combination of fibrates with ursodeoxycholic acid: French-Spanish experience.
Lemoinne S; Pares A; Reig A; Ben Belkacem K; Kemgang Fankem AD; Gaouar F; Poupon R; Housset C; Corpechot C; Chazouillères O
Clin Res Hepatol Gastroenterol; 2018 Dec; 42(6):521-528. PubMed ID: 30100231
[TBL] [Abstract][Full Text] [Related]
22. Effects of Bezafibrate on Outcome and Pruritus in Primary Biliary Cholangitis With Suboptimal Ursodeoxycholic Acid Response.
Reig A; Sesé P; Parés A
Am J Gastroenterol; 2018 Jan; 113(1):49-55. PubMed ID: 29016567
[TBL] [Abstract][Full Text] [Related]
23. Budesonide or prednisone in combination with ursodeoxycholic acid in primary sclerosing cholangitis: a randomized double-blind pilot study. Belgian-Dutch PSC Study Group.
van Hoogstraten HJ; Vleggaar FP; Boland GJ; van Steenbergen W; Griffioen P; Hop WC; van Hattum J; van Berge Henegouwen GP; Schalm SW; van Buuren HR
Am J Gastroenterol; 2000 Aug; 95(8):2015-22. PubMed ID: 10950051
[TBL] [Abstract][Full Text] [Related]
24. Medical and endoscopic therapy of primary sclerosing cholangitis.
Weismüller TJ; Lankisch TO
Best Pract Res Clin Gastroenterol; 2011 Dec; 25(6):741-52. PubMed ID: 22117639
[TBL] [Abstract][Full Text] [Related]
25. Chronic cholestatic diseases.
Poupon R; Chazouillères O; Poupon RE
J Hepatol; 2000; 32(1 Suppl):129-40. PubMed ID: 10728800
[TBL] [Abstract][Full Text] [Related]
26. [Efficacy of combined administration of ursodeoxycholic acid and hepthral in the treatment of primary biliary cirrhosis].
Avezov SA; Mansurov FKh
Klin Med (Mosk); 2004; 82(3):55-8. PubMed ID: 15114777
[TBL] [Abstract][Full Text] [Related]
27. Overlap syndrome of primary biliary cirrhosis and autoimmune hepatitis: a retrospective study of 115 cases of autoimmune liver disease.
Heurgué A; Vitry F; Diebold MD; Yaziji N; Bernard-Chabert B; Pennaforte JL; Picot R; Louvet H; Frémond L; Geoffroy P; Schmit JL; Cadiot G; Thiéfin G
Gastroenterol Clin Biol; 2007 Jan; 31(1):17-25. PubMed ID: 17273128
[TBL] [Abstract][Full Text] [Related]
28. A preliminary trial of high-dose ursodeoxycholic acid in primary sclerosing cholangitis.
Mitchell SA; Bansi DS; Hunt N; Von Bergmann K; Fleming KA; Chapman RW
Gastroenterology; 2001 Oct; 121(4):900-7. PubMed ID: 11606503
[TBL] [Abstract][Full Text] [Related]
29. Single or multiple dose ursodeoxycholic acid for cholestatic liver disease: biliary enrichment and biochemical response.
van de Meeberg PC; Wolfhagen FH; Van Berge-Henegouwen GP; Salemans JM; Tangerman A; van Buuren HR; van Hattum J; van Erpecum KJ
J Hepatol; 1996 Dec; 25(6):887-94. PubMed ID: 9007717
[TBL] [Abstract][Full Text] [Related]
30. [Autoimmune cholestasis syndrome. Ursodeoxycholic acid is the drug standard].
Stiefelhagen P
MMW Fortschr Med; 2007 May; 149(21):49. PubMed ID: 17668736
[No Abstract] [Full Text] [Related]
31. Primary sclerosing cholangitis: updates in diagnosis and therapy.
Portincasa P; Vacca M; Moschetta A; Petruzzelli M; Palasciano G; van Erpecum KJ; van Berge-Henegouwen GP
World J Gastroenterol; 2005 Jan; 11(1):7-16. PubMed ID: 15609388
[TBL] [Abstract][Full Text] [Related]
32. Novel Aspects in the Management of Cholestatic Liver Diseases.
Chazouillères O
Dig Dis; 2016; 34(4):340-6. PubMed ID: 27170387
[TBL] [Abstract][Full Text] [Related]
33. Combination therapy of ursodeoxycholic acid and budesonide for PBC-AIH overlap syndrome: a meta-analysis.
Zhang H; Yang J; Zhu R; Zheng Y; Zhou Y; Dai W; Wang F; Chen K; Li J; Wang C; Li S; Liu T; Abudumijiti H; Zhou Z; Wang J; Lu W; Wang J; Xia Y; Zhou Y; Lu J; Guo C
Drug Des Devel Ther; 2015; 9():567-74. PubMed ID: 25632224
[TBL] [Abstract][Full Text] [Related]
34. [Treatment of cholestatic liver diseases].
Karvonen AL
Duodecim; 2003; 119(6):533-9. PubMed ID: 12708340
[No Abstract] [Full Text] [Related]
35. Guidelines for therapy of autoimmune liver disease.
Ishibashi H; Komori A; Shimoda S; Gershwin ME
Semin Liver Dis; 2007 May; 27(2):214-26. PubMed ID: 17520519
[TBL] [Abstract][Full Text] [Related]
36. Primary biliary cirrhosis-autoimmune hepatitis overlap syndrome: clinical features and response to therapy.
Chazouillères O; Wendum D; Serfaty L; Montembault S; Rosmorduc O; Poupon R
Hepatology; 1998 Aug; 28(2):296-301. PubMed ID: 9695990
[TBL] [Abstract][Full Text] [Related]
37. [Research progress on risk factors for poor response of ursodeoxycholic acid in primary biliary cholangitis].
Yuan Z; Jia G; Han Y
Zhonghua Gan Zang Bing Za Zhi; 2019 Jan; 27(1):73-76. PubMed ID: 30685931
[TBL] [Abstract][Full Text] [Related]
38. Molecular mechanisms of ursodeoxycholic acid toxicity & side effects: ursodeoxycholic acid freezes regeneration & induces hibernation mode.
Kotb MA
Int J Mol Sci; 2012; 13(7):8882-8914. PubMed ID: 22942741
[TBL] [Abstract][Full Text] [Related]
39. Overlap syndromes.
Beuers U; Rust C
Semin Liver Dis; 2005 Aug; 25(3):311-20. PubMed ID: 16143946
[TBL] [Abstract][Full Text] [Related]
40. Development of autoimmune hepatitis in primary biliary cirrhosis.
Gossard AA; Lindor KD
Liver Int; 2007 Oct; 27(8):1086-90. PubMed ID: 17845536
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
